Accéder au contenu
Merck

Lentinan in-situ coated tungsten oxide nanorods as a nanotherapeutic agent for low power density photothermal cancer therapy.

International journal of biological macromolecules (2019-06-30)
Yilong Tian, Wenhui Yi, Lei Bai, Ping Zhang, Jinhai Si, Xun Hou, Yating Deng, Jin Hou
RÉSUMÉ

Development of high photothermal performance and biocompatible nanotherapeutic agents is of great importance for photothermal cancer treatment. In this paper, we have developed lentinan decorated tungsten oxide nanorods (W18O49@LTN NRs) via a mild one-step solvothermal route. Owing to the numerous surface hydroxyl groups of polymer chains, the presence of lentinan layer in the surface of W18O49 NRs lead to good biocompatibility. The lentinan layer also affects the crystal structure of W18O49 and improves near-infrared absorption (~1.7 × 109 M-1 cm-1 at 980 nm), which is two orders of higher than previously reported PEGylated W18O49 nanowires. Even under near-infrared (NIR) laser irradiation at a very low power density of 0.4 W/cm2, the temperature of W18O49@LTN NRs aqueous dispersion (125 μg/mL) could increase by 15.1 °C. The photothermal conversion efficiency of W18O49@LTN NRs reaches 33.86%, which is higher than previously reported WO3-x hierarchical nanostructures (28.1%). Importantly, when cancer cells were treated with W18O49@LTN NRs (200 μg/mL) and 980 nm laser (0.4 W/cm2), a significant photo-induced cell killing behavior was observed. This work demonstrates that W18O49@LTN NRs have the potential for precise cancer treatment.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Tungsten(IV) chloride, 95%